Skip to main content

Table 2 Outcomes of Eight Patients with Preexisting Cardiomyopathy Undergoing Anthracycline Chemotherapy for Any Cancer, With or Without The Cardioprotectant, Dexrazoxane

From: Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

Patient #. Sex; age, years Elevated biomarker concentrationsa Clinical HF New arrhythmia Clinical outcome Chemotherapy cycles received, n Cancer outcomes
Troponin BNP
Without dexrazoxane
 1. M; 87 Not available Not available Yes NSVT Cardiogenic shock, HF, death 6 Died
 2. M; 66 Not available Not available Yes No Cardiogenic shock, HF, death 3 Died
 3. M; 65 Not available Not available Yes No Required ICD 2 Alive at 12 months after Allo SCT
With dexrazoxane
 4. F; 67 No No No NSVT Alive at 30 months 6 Complete remission
 5. F; 75 No No No No Alive at 18 months, Needed BiV ICD implantation 6 Complete remission
 6. F 70 No No No No Alive at 12 months 6 Partial response
 7. M; 73 No No No No Alive at 15 months 6 Complete remission
 8. F; 68 No No No NSVT Alive at 12 months 6 Complete response
  1. NSVT Non-sustained ventricular tachycardia, HF heart failure, ICD implantable cardiodefibrillator, Allo SCT allogeneic stem cell transplantation, BiV ICD bi-ventricular implantable cardiodefibrillator
  2. aThreshold values for elevation were > 0.03 ng/mL for cTnI and > 250 pg/mL for BNP